Posted by Michael Wonder on 28 May 2024
Vera Therapeutics receives US FDA breakthrough therapy designation for atacicept in immunoglobulin A nephropathy
28 May 2024 - Vera Therapeutics today announced that the US FDA has granted breakthrough therapy designation to atacicept for the treatment of immunoglobulin A nephropathy.
The designation reflects the FDA’s determination that, based on an assessment of data from the Phase 2b ORIGIN clinical trial of atacicept for immunoglobulin A nephropathy, atacicept may demonstrate substantial improvement on a clinically significant endpoint over available therapies for patients with immunoglobulin A nephropathy.
